scholarly journals SMACKtivism: A Program Redesign so Good, You Won’t Know What Hit You

Author(s):  
Tiffany Karalis Noel ◽  
Julie Gorlewski ◽  
Erin Kearney

This essay describes the context, mission, guiding principles, signature pedagogies, curriculum, and anticipated benefits and limitations of our newly designed EdD in Learning and Teaching in Social Contexts. As we prepare to launch our new program (pending approval), our key development efforts are focused on implementing leading-edge coursework centering on problems of practice through a blend of online interactions and applied, real-world experiences. Our primary objective is to equip scholar-practitioners with the expertise to initiate and sustain systematic approaches to transformative and justice-oriented improvement within their local educational communities, both during and following their time in the program.

2018 ◽  
pp. 216-236
Author(s):  
Samantha Analuz Quiroz Rivera ◽  
Ruth Rodríguez Gallegos

Mathematics cannot be reduced to the use of algorithms. The main objective of teaching mathematics in school is their application in real world situations. Mathematical modeling was born as an answer of this concerned and implies the relation between mathematics and applications. Because of that, teachers need to be correctly training in the use of mathematical modeling in their daily lesson plans. The aim of this study is to propose a methodology for help teachers purchase mathematical modeling as a strategy to teach mathematics. Our methodology is based on the analysis of teachers' conceptions about learning and teaching mathematics and after that promote their evolution. The main characteristic is the collaborative work between teachers and the researcher in cycles of discussion and classes' implementation. The evidence showed that teachers can actually change their conceptions about what is needed for teaching mathematics and design lesson plans using mathematical modeling.


Author(s):  
Samantha Analuz Quiroz Rivera ◽  
Ruth Rodríguez Gallegos

Mathematics cannot be reduced to the use of algorithms. The main objective of teaching mathematics in school is their application in real world situations. Mathematical modeling was born as an answer of this concerned and implies the relation between mathematics and applications. Because of that, teachers need to be correctly training in the use of mathematical modeling in their daily lesson plans. The aim of this study is to propose a methodology for help teachers purchase mathematical modeling as a strategy to teach mathematics. Our methodology is based on the analysis of teachers' conceptions about learning and teaching mathematics and after that promote their evolution. The main characteristic is the collaborative work between teachers and the researcher in cycles of discussion and classes' implementation. The evidence showed that teachers can actually change their conceptions about what is needed for teaching mathematics and design lesson plans using mathematical modeling.


Author(s):  
Kara Dawson ◽  
Swapna Kumar

In this chapter the authors share the guiding principles for professional practice dissertations developed and studied within their online EdD in Educational Technology at the University of Florida. While these guiding principles were developed approximately four years before the call for chapters for this book was released, they align nicely with at least three pertinent themes that frame this book (i.e. the importance of addressing critical problems of practice, applying research rigor involving real theory and inquiry and demonstrating impact of research). The authors make explicit connections between their guiding principles and these themes and provide examples of how the themes have played out in dissertations completed in their program. The authors then provide implications for others seeking to structure (or restructure) the way dissertations are conceptualized in their professional practice problems.


1999 ◽  
Vol 13 (4) ◽  
pp. 267-276 ◽  
Author(s):  
David Laughton ◽  
Roger Ottewill

As part of their attempt to embed their teaching more firmly in the ‘real world’ of business, some university tutors have incorporated ‘commissioned’ or ‘live’ projects into their learning and teaching strategies. These projects enable students to make a direct contribution to their business clients while simultaneously fulfilling key educational objectives. Drawing on their experience of the use of commissioned projects on an MSc in International Business (MSclB) course, the authors analyse in detail both the potential benefits and the problems that arise in implementing such schemes. In this paper, they outline some of the key features of the MSclB course, focusing on the commissioned project component; indicate the reasons for using commissioned projects from the point of view of both tutors and students; describe and evaluate the methodology used to generate data for informing the identification and discussion of issues; and explore a number of key factors for tutors and students in the use of commissioned projects. The paper thus raises awareness of the nature of commissioned projects as a pedagogic tool and of what needs to be done if their contribution to the enhancement of students' understanding of the business world is to be maximized.


Anthropology ◽  
2012 ◽  
Author(s):  
Barbara Rose Johnston

As a term and a subject area, applied anthropology refers to that broad array of research, methods, and outcomes developed and used for the explicit purpose of recognizing, understanding, and addressing human problems. It has been described both as the fifth field of anthropology and as the bridging discipline since the application of research and knowledge to social problems cross-cuts all fields of anthropology. Some view applied anthropology narrowly, in terms of work conducted outside of university settings that is typically defined and produced under some form of contractual relationship, with services and resulting products used in some sort of problem-solving way. In this usage, applied anthropologists work to resolve problems, often in technocratic contexts, with theoretically informed praxis that generates and refines methodologies though rarely contributes toward the production of theory. For others, applied anthropology has broader meaning and refers to the varied uses of anthropology in public and private settings, including academia, where the primary objective involves problem-focused concerns. In this usage all forms of anthropological endeavor have social meaning and an applied dimension. Both the varied meanings of term and the varied outcomes of endeavor reflect the political economic conditions, social contexts, and identity politics within the discipline as it has been practiced over the past century, especially in the United States, Canada, and Great Britain. Classification and restricted access agreements imposed by research sponsors (governments, other international institutions, and corporations), limited peer review, publication and distribution of grey literature reports, and the membership-restricted publication of flagship journals historically reinforced the boundaries between university-based anthropologists and applied practitioners. With the advent of the web, library scanning projects, changes in information disclosure laws, the ease of uploading the collected works of various journals, newsletters, and magazines to the web, and the increased sophistication and use of web-based translation, access to the collective works in applied anthropology has never been greater. Increasingly, the distinction between applied and four-field anthropology has relatively less meaning as anthropologists are engaged as disciplinary and public actors in a wide array of scholarly, practical, and advocacy endeavors. Globally, anthropological work involves and is celebrated for its combined theoretical, applied, and practical contributions to society.


2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 293-293
Author(s):  
Fadi S. Braiteh ◽  
Monika Parisi ◽  
Quanhong Ni ◽  
Si yeon Park ◽  
Claudio Faria

293 Background: In a phase III study in MBC, nab-P demonstrated anti-tumor activity across lines of therapy. Eribulin is indicated for the treatment (Tx) of MBC in pts who have previously received ≥ 2 chemotherapeutic regimens. This analysis evaluated Tx patterns and effectiveness of nab-P and eribulin in pts with MBC in a real-world community-based setting. Methods: A retrospective cohort study was performed using fully de-identified data from a US electronic medical record platform of 1300 community oncology physicians. The analysis included women aged ≥ 18 years with MBC who started on nab-P or eribulin monotherapy as 1L or 2L Tx from 12/4/10 to 10/6/14 (≥ 1 cycle of nab-P or eribulin required). The primary objective was to examine duration of Tx (DOT, including time to Tx discontinuation [TTD]; censored if last administration > 30 days from the last date in the database) and time to next Tx (TTNT; day 1 from drug 1 to drug 2). Incidence of adverse events (AEs) and supportive care used during Tx were also examined. Results: Pt characteristics were similar between groups. Mean age was 59 years. Most pts had hormone receptor + (62%), HER2− (82%) disease, and 1L therapy (60%). More pts received nab-P vs eribulin. Slightly more pts receiving nab-P vs eribulin were treated in 1L (63% vs 55%). DOT, TTNT, and TTD were significantly longer in the nab-P vs eribulin group (Table). Thrombocytopenia and anemia were numerically lower in the nab-P vs eribulin group (P = 0.11 for each). Nausea/vomiting was less common with eribulin vs nab-P (P = 0.009). Granulocyte-colony stimulating factor, hydrating agents, and antiemetics were used less often in pts receiving nab-P (P < 0.01 for each). Conclusions: DOT, TTNT, and TTD were significantly longer for pts treated with nab-P vs eribulin. Moreover, pts receiving nab-P experienced fewer hematologic AEs and utilized fewer doses of supportive care. [Table: see text]


2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 542-542 ◽  
Author(s):  
Laurence Albiges ◽  
Sylvie Negrier ◽  
Cécile Dalban ◽  
Christine Chevreau ◽  
Gwenaelle Gravis ◽  
...  

542 Background: NIVOREN GETUG AFU 26 study, is a French multicenter prospective study to evaluate safety and efficacy of Nivolumab (N) in a broad “real world setting” in mRCC after failure of 1 or 2 tyrosine kinase inhibitors. Methods: Between February 2016 and June 2017, 729 pts have been enrolled across 27 institutions. Primary objective of the trial was safety assessed by grade ≥ 3 treatment related adverse event (TRAE). Results: Overall, 720 patients treated with N were included in this final analysis. All pts had clear cell mRCC. Median age was 64 years old, 77.4% were male, 84.7% had prior nephrectomy. ECOG PS was >1 in 15.0%, 21.3% pts had received prior everolimus, 22.4% pts had received more than 2 previous lines, IMDC risk groups were 18.3%/56.2%/25.5% for good/intermediate and poor risk respectively. Brain Metastasis at screening was noted in 83 (12.3%) pts. With a median follow up of 20.9 months (mo), median duration of treatment was 5.2 mo (0.5; 28.1) with 15% of pts still on therapy. Median PFS was 3.2 IC 95% [2.9; 4.6] mo. At the time of this analysis, 316 pts have died and 12 mo OS rate was 69% IC 95% [66; 73]. Objective response rate was 20.8% (1.2% CR, 19.6%PR). Stable disease was seen in 31.6% and PD in 47.6%. Noteworthy, 46.1% of pts were treated beyond progression. Overall, 123 pts (17.1%) have presented at least one grade ≥ 3 TRAE, including asthenia (2.4%), metabolic disorders (2.1%), gastro-intestinal disorders (1 .9%), musculoskeletal (1.7%), renal disorders (1.3%), hematologic (1.3%). 6 patients have developed grade 5 toxicity (2 cardiac failure, 1 macrophage activation syndrom, 1 Cerebral hemorrhage, 1 unknown). Treatment discontinuation due to any grade TRAE occurred in 54 pts (7.5%). Interestingly, pts with grade ≥ 3 TRAE had longer PFS than pts without grade ≥ 3 TRAE (HR 0.69 [0.55-0.87]). Conclusions: We report the primary objective analysis of the largest prospective real world setting study of N in mRCC. NIVOREN study demonstrates that N safety and efficacy in a “real world” prospective study are similar to the pivotal study. Grade ≥ 3 TRAE was associated with longer PFS. Clinical trial information: NCT03013335.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13085-e13085
Author(s):  
Jordyn Paige Higgins ◽  
Chloe Lalonde ◽  
Kristina F. Byers ◽  
Christine Davis ◽  
Kandra Horne ◽  
...  

e13085 Background: The specifics of the salvage regimen gemcitabine/carboplatin (G/C) in metastatic breast cancer (MBC) are not well-characterized and are limited to the clinical trial setting, which often excludes heavily pretreated patients with high disease burden and velocity. The primary objective of this study is to assess real-world outcomes in patients with MBC treated with G/C. Methods: A retrospective chart review was conducted on adults with MBC who received >1 dose of G/C at Emory Healthcare / Winship Cancer Institute from December 1, 2005 to April 30, 2019 (n = 109). Patients were stratified by receptor status (hormone receptor (HR), triple-negative (TN), and human epidermal growth factor receptor-2 (HER2)). Results: Patients were heavily pretreated (median 2 lines, range 0-11) and had extensive metastatic disease (median 3 sites, range 1-6). The median starting doses were carboplatin AUC 2 (range: 1.5-5) and gemcitabine 1000 mg/m2 (range 400-1100). The median cycle length was 21 days (range 14-28). The median progression-free survival (mPFS) was 3.7 months and median overall survival (mOS) was 7.7 months. OS at 24 months was 23.1%. Previous immunotherapy, radiation for palliation, or historical receipt of neoadjuvant/adjuvant cytotoxic therapy was significantly associated with improved survival outcomes, while possessing lung, liver, or bone metastases was significantly associated with worse survival outcomes. The presence of brain metastases did not correlate with outcomes. Side effect/intolerance led to dosing and scheduling adjustments in 38.5% and 49.5% of patients, respectively, and resulted in treatment discontinuation in 21% of patients. Hospitalization occurred in 51.4% of patients on treatment. Conclusions: G/C is a safe and effective regimen in real-world MBC patients regardless of receptor subtype. Even low doses of G/C may provide some CNS penetration and control. Improved survival outcomes associated with previous immunotherapy and radiation for palliation may be due to disease control or carry over effect and warrant further study. [Table: see text]


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16042-e16042
Author(s):  
Qirong Geng ◽  
Wenxiu Cheng ◽  
Zhiyu Chen ◽  
Wen Zhang ◽  
Xiaodong Zhu ◽  
...  

e16042 Background: Cetuximab provides a clear clinical benefit in the treatment in patients with RAS wild-type mCRC irrespective of treatment line, but the best sequence is still under investigation. Methods: Patients with RAS wild-type mCRC (2011-2019) who received cetuximab therapy were retrospectively analyzed. They were stratified based on the cetuximab treatment sequence, into the 1st, 2nd, 3rd or later-lines groups. The primary objective was to investigate the impact on Cetuximab sequence (2nd vs. 3rd and later-line) in PFS and OS. As for patients received the 3rd or later-line cetuximab with irinotecan therapy after refractory to the prior 1st and 2nd-line combined chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan, they will get another PFS of 2nd-line chemotherapy (PFSchemo) besides the PFS of 3rd or later-line cetuximab compared with the cetuximab 2nd-line used patients. We combined the PFSchemo to the PFS of 3rd or later-line cetuximab, then compared with PFS of 2nd -line cetuximab to evaluate the primary objective in PFS. As for the OS of primary objective, we calculated it from start of the 2nd-line of treatment. The secondary objective was to compare the efficacy of cetuximab sequence (1st vs. 2nd and later-lines) in OS calculated from start of the 1st-line of treatment. Results: In total, 193 patients were included: 106 in the 1st, 41 in the 2nd, and 46 in the 3rd-line groups. No difference was observed in baseline characteristics as sex,age,site of primary tumour,number of metastatic sites in the three groups. The median PFS of the 2nd-line and 3rd or later-line groups were 7.1 (95% CI 6.39-7.80) and 13.87 months(95% CI 11.44-16.29) respectively. PFS of the 3rd or later-line group was significantly longer than that of the 2nd-line group (hazard ratio[HR], 0.552; 95% CI, 0.349 to 0.871; P = 0.01). Median OS was 17.8 months (95% CI 13.5-22.1) in the 2nd-line and 27.4 months (95% CI 20.69-34.16) in the 3rd or later-line group (HR, 0.597; 95% CI 0.341 to 1.043; P = 0.07) from start of 2nd-line therapy. The median OS was 28.17 months (95% CI 22.11-34.22) in the 1st-line group and 33.10 months (95% CI 26.88-39.31) in the 2nd and later-lines group (HR, 0.724; 95% CI 0.507 to 1.304; P = 0.075) calculated from the 1st-line of therapy. Conclusions: In a real-world cohort we found that later-line especially 3rd or later-line therapy of cetuximab, may be more benefit for patients with RAS wild type mCRC, as 3rd or later-line use of cetuximab give one more line therapy chance.


Sign in / Sign up

Export Citation Format

Share Document